Eddy Edson
Well-Known Member
- Relationship to Diabetes
- Type 2
The annual update to the American Diabetes Association's standard of care guidelines has been published: https://diabetesjournals.org/care/issue/46/Supplement_1
This is a comprehensive, detailed and up-to-date compendium of evidence-based guidelines for the treatment of T1D and T2D and complications.
An article with an overview of the changes in this update: https://www.clinicaladvisor.com/hom...ormation-center/2023-standards-care-diabetes/
The Standards of Care in Diabetes—2023 includes new recommendations on achieving more intensive weight loss goals using newer medications, targeting lower blood pressure and cholesterol goals, using SGLT2 inhibitors for patients with heart failure, and addressing social determinants of health in the delivery of care, according to the American Diabetes Association (ADA).
“It is no longer just glycemic control, it is really glycemic control plus weight management and cardiorenal protection,” said Robert A. Gabbay, MD, PhD, FACP, chief scientific and medical officer for the ADA.
Dr Gabbay highlighted 3 themes in the updated recommendations that may have the greatest effects on patient health: more aggressive weight management, the importance of the diabetes care team in addressing social determinants of health [economic stability, health care quality, social and community context, neighborhood and environment, education access], and more aggressive strategies to reduce cardiovascular disease through lower blood pressure and LDL cholesterol goals.
This is a comprehensive, detailed and up-to-date compendium of evidence-based guidelines for the treatment of T1D and T2D and complications.
An article with an overview of the changes in this update: https://www.clinicaladvisor.com/hom...ormation-center/2023-standards-care-diabetes/
The Standards of Care in Diabetes—2023 includes new recommendations on achieving more intensive weight loss goals using newer medications, targeting lower blood pressure and cholesterol goals, using SGLT2 inhibitors for patients with heart failure, and addressing social determinants of health in the delivery of care, according to the American Diabetes Association (ADA).
“It is no longer just glycemic control, it is really glycemic control plus weight management and cardiorenal protection,” said Robert A. Gabbay, MD, PhD, FACP, chief scientific and medical officer for the ADA.
Dr Gabbay highlighted 3 themes in the updated recommendations that may have the greatest effects on patient health: more aggressive weight management, the importance of the diabetes care team in addressing social determinants of health [economic stability, health care quality, social and community context, neighborhood and environment, education access], and more aggressive strategies to reduce cardiovascular disease through lower blood pressure and LDL cholesterol goals.